Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
06/26/18Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock
CINCINNATI--(BUSINESS WIRE)--Jun. 26, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announced today the pricing of the previously announced underwritten public offe... 
Printer Friendly Version
06/25/18Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
CINCINNATI--(BUSINESS WIRE)--Jun. 25, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced that it intends to sell, subject to market and other conditions, $40 million of its common stock in an underwritten public offering. Aerpio also intends to grant the underwriters a 30-day option to purchase an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. Aerpio also announced that its comm... 
Printer Friendly Version
06/25/18Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
CINCINNATI & SAN DIEGO--(BUSINESS WIRE)--Jun. 25, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced an exclusive global license agreement with a wholly owned subsidiary of Gossamer Bio, Inc., GB004, Inc. (“Gossamer”), for the development and commercialization of Aerpio’s HIF-1 alpha stabilizer, AKB-4924, along with other related compounds. The arrangement combines Aerpio’s deep understanding of HIF biology with Gossamer’s experience i... 
Printer Friendly Version
05/31/18Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--May 31, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018 at 1:30 p.m. Eastern Time in New York, NY. Dr. Hoffmann will provide a corporate overview and business update. ... 
Printer Friendly Version
05/22/18Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
CINCINNATI--(BUSINESS WIRE)--May 22, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer, AKB-4924. AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease (IBD). “Unlike oth... 
Printer Friendly Version
05/15/18Aerpio Pharmaceuticals Announces Nomination of Industry Veteran Cheryl Cohen to Board of Directors
CINCINNATI--(BUSINESS WIRE)--May 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced the nomination of a new director, Cheryl Cohen, to its Board of Directors. Ms. Cohen will stand for election at Aerpio’s 2018 Annual Meeting of Stockholders on June 20, 2018. If approved, Ms. Cohen will bring to Aerpio more than 25 years of experience in the ... 
Printer Friendly Version
05/15/18Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track CINCINNATI--(BUSINESS WIRE)--May 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the first quarter ended March 31, 2018. Stephen Hoffman, M.D. Ph.D., Chief Executive Officer of Aerpio, commented,... 
Printer Friendly Version
05/04/18Aerpio Announces Presentations on Novel Treatments for Glaucoma and Retinal Diseases at ARVO 2018 Annual Meeting
CINCINNATI--(BUSINESS WIRE)--May 4, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, presented new preclinical and clinical results for several of its development programs at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting in Honolulu, HI this week. The three presentations are listed below: Subcutan... 
Printer Friendly Version
03/20/18Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business ... 
Printer Friendly Version
03/15/18Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Mar. 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that President and Founder, Joseph Gardner, Ph.D., will present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00 a.m. Eastern Time in New York, N.Y. Dr. Gardner will provide a corporate overview and business update. ... 
Printer Friendly Version
03/13/18Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today, March 13th at 8:30 a.m. ET CINCINNATI--(BUSINESS WIRE)--Mar. 13, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. ... 
Printer Friendly Version
03/07/18Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, March 13, 2018
CINCINNATI--(BUSINESS WIRE)--Mar. 7, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its fourth quarter and full year 2017 financial results will be released before the market opens on Tuesday, March 13, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss the Company’... 
Printer Friendly Version
03/06/18Aerpio Pharmaceuticals to Present at the Cowen 38th Annual Health Care Conference
CINCINNATI--(BUSINESS WIRE)--Mar. 6, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cowen 38th Annual Health Care Conference on Monday, March 12, 2018 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Hoffman will provide a corporate overview and business upda... 
Printer Friendly Version
02/28/18Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury
CINCINNATI--(BUSINESS WIRE)--Feb. 28, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today that renal function data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) was presented at the Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury in Santa Fe, New Mexico. ... 
Printer Friendly Version
02/09/18Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
CINCINNATI--(BUSINESS WIRE)--Feb. 9, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today the completion of patient enrollment in the company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate AKB-9778 for patients with moderate to severe non-proliferative diabetic ret... 
Printer Friendly Version